The development of drugs such as Vemurafenib and Dabrafenib, which selectively inhibit BRAFV600E, the most frequent BRAF mutation, represents a major breakthrough in melanoma treatment, triggering a response rate of 80% in phase I clinical trials and an overall survival benefit in phase III studies4, 5. Here, BRAF is linked to melanoma.